Frequency Therapeutics Investor Event: Preparing for FX-322 Phase 2b Data

Frequency Therapeutics Investor Event: Preparing for FX-322 Phase 2b Data

December 13, 2022

Frequency Therapeutics hosted a virtual investor event on December 13, 2022. The primary focus was FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). Company management reviewed the FX-322 Phase 2b study design, the patient populations targeted for enrollment, pre-specified speech perception endpoints, and the potential FX-322 commercial market opportunity. Key opinion leaders (KOLs) also provided insight into the potential impact of a pharmaceutical intervention for patients with SNHL, how a medicine for cochlear regeneration may fit with currently available hearing devices, and the clinical significance of speech perception on overall hearing.

FX-322-208 study design, applied learnings, and endpoints by Kevin Franck, Phd
Kevin Franck, PhD
SVP, Strategic Marketing and New Product Planning
The Importance of Understanding Speech
Christina L. Runge, MA, PhD, CCC-A, FAAA
Professor, Otolaryngology and Communication Sciences, Medical College of Wisconsin
The Role of Physicians in the Treatment of SNHL and the Opportunity for a Hearing Restoration Therapeutic
Anthony Mikulec, MD
Professor of Otology & Neurotology at St. Louis University and SSM Health
Commercial Opportunity for Hearing Therapeutics
Kevin Franck, PhD
SVP, Strategic Marketing and New Product Planning